Suppr超能文献

种族导致药物洗脱支架使用的差异时有时无。

Disappearing and reappearing differences in drug-eluting stent use by race.

机构信息

Department of Health Policy and Management, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7411, USA.

出版信息

J Eval Clin Pract. 2013 Apr;19(2):256-62. doi: 10.1111/j.1365-2753.2011.01809.x. Epub 2011 Dec 2.

Abstract

RATIONALE, AIMS AND OBJECTIVES: Drug-eluting coronary stents (DES) rapidly dominated the marketplace in the United States after approval in 2003, but utilization rates were initially lower among African American patients. We assess whether racial differences persisted as DES diffused into practice.

METHODS

Medicare claims data were used to identify coronary stenting procedures among elderly patients with acute coronary syndromes (ACS). Regression models of the choice of DES versus bare mental stent controlled for demographics, ACS type, co-morbidities and hospital characteristics. Diffusion was assessed in the short run (2003-2004) and long run (2007), with the effect of race calculated to allow for time-varying effects.

RESULTS

The sample included 381,887 Medicare beneficiaries treated with stent insertion; approximately 5% were African American. Initially (May 2003-February 2004), African American race was associated with lower DES use compared to other races (44.3% versus 46.5%, P < 0.01). Once DES usage was high in all patients (March-December 2004), differences were not significant (79.8% versus 80.3%, P = 0.45). Subsequent concerns regarding DES safety caused reductions in DES use, with African Americans having lower use than other racial groups in 2007 (63.1% versus 65.2%, P < 0.01).

CONCLUSIONS

Racial disparities in DES use initially disappeared during a period of rapid diffusion and high usage rates; the reappearance of disparities in use by 2007 may reflect DES use tailored to unmeasured aspects of case mix and socio-economic status. Further work is needed to understand whether underlying differences in race reflect decisions regarding treatment appropriateness.

摘要

背景、目的和目标:药物洗脱冠状动脉支架(DES)于 2003 年获得批准后,迅速主导了美国市场,但最初非洲裔美国患者的使用率较低。我们评估了随着 DES 在实践中的传播,种族差异是否仍然存在。

方法

使用医疗保险索赔数据,在患有急性冠状动脉综合征(ACS)的老年患者中识别冠状动脉支架置入术。DES 与裸金属支架选择的回归模型控制了人口统计学、ACS 类型、合并症和医院特征。在短期内(2003-2004 年)和长期(2007 年)评估了扩散情况,并计算了种族的影响,以考虑时间变化的影响。

结果

该样本包括 381,887 名接受支架置入术治疗的医疗保险受益人;约 5%为非裔美国人。最初(2003 年 5 月至 2004 年 2 月),与其他种族相比,非裔美国人种族与较低的 DES 使用相关(44.3%比 46.5%,P<0.01)。一旦所有患者的 DES 使用量都很高(2004 年 3 月至 12 月),差异就不显著(79.8%比 80.3%,P=0.45)。随后,DES 的安全性问题导致 DES 使用减少,2007 年非裔美国人的使用量低于其他种族群体(63.1%比 65.2%,P<0.01)。

结论

DES 使用的种族差异最初在快速扩散和高使用率期间消失;2007 年使用率再次出现差异可能反映了针对病例组合和社会经济地位未测量方面的 DES 使用调整。需要进一步研究以了解种族差异背后是否反映了对治疗适宜性的决策。

相似文献

1
Disappearing and reappearing differences in drug-eluting stent use by race.
J Eval Clin Pract. 2013 Apr;19(2):256-62. doi: 10.1111/j.1365-2753.2011.01809.x. Epub 2011 Dec 2.
2
African-American patients are less likely to receive drug-eluting stents during percutaneous coronary intervention.
Cardiovasc Revasc Med. 2014 Jun;15(4):214-8. doi: 10.1016/j.carrev.2014.04.003. Epub 2014 Apr 12.
3
Racial Differences in Quality of Care and Outcomes After Acute Coronary Syndrome.
Am J Cardiol. 2018 Jun 15;121(12):1489-1495. doi: 10.1016/j.amjcard.2018.02.036. Epub 2018 Mar 13.
5
Differences in utilization of drug-eluting stents by race and payer.
Am J Cardiol. 2007 Oct 15;100(8):1192-8. doi: 10.1016/j.amjcard.2007.05.039. Epub 2007 Aug 2.
8
Drug-eluting compared with bare-metal coronary stents among elderly patients.
J Am Coll Cardiol. 2008 May 27;51(21):2017-24. doi: 10.1016/j.jacc.2008.01.057.

本文引用的文献

3
Take-up of Medicare Part D: results from the Health and Retirement Study.
J Gerontol B Psychol Sci Soc Sci. 2010 Jul;65(4):492-501. doi: 10.1093/geronb/gbp107. Epub 2009 Dec 24.
5
Deaths: final data for 2006.
Natl Vital Stat Rep. 2009 Apr 17;57(14):1-134.
6
Racial disparities in outcomes following percutaneous coronary intervention with drug-eluting stents.
Am J Cardiol. 2009 Mar 1;103(5):653-8. doi: 10.1016/j.amjcard.2008.10.043. Epub 2009 Jan 17.
7
Differences in utilization of drug-eluting stents by race and payer.
Am J Cardiol. 2007 Oct 15;100(8):1192-8. doi: 10.1016/j.amjcard.2007.05.039. Epub 2007 Aug 2.
9
Stent thrombosis redux--the FDA perspective.
N Engl J Med. 2007 Mar 8;356(10):984-7. doi: 10.1056/NEJMp068304. Epub 2007 Feb 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验